Alnylam Pharmaceuticals (ALNY) Getting Somewhat Positive Press Coverage, Study Finds

Media stories about Alnylam Pharmaceuticals (NASDAQ:ALNY) have been trending somewhat positive on Monday, Accern Sentiment reports. The research firm ranks the sentiment of media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Alnylam Pharmaceuticals earned a media sentiment score of 0.12 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 45.773786234313 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Here are some of the news headlines that may have effected Accern Sentiment’s analysis:

How to Become a New Pot Stock Millionaire

ALNY traded down $4.92 during midday trading on Monday, reaching $95.84. The company’s stock had a trading volume of 1,065,751 shares, compared to its average volume of 1,011,583. The stock has a market cap of $10,093.27, a PE ratio of -17.68 and a beta of 2.68. The company has a debt-to-equity ratio of 0.02, a quick ratio of 12.23 and a current ratio of 12.23. Alnylam Pharmaceuticals has a 1 year low of $49.12 and a 1 year high of $153.99.



Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, February 8th. The biopharmaceutical company reported ($1.48) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.38) by ($0.10). The business had revenue of $37.90 million during the quarter, compared to analysts’ expectations of $19.31 million. Alnylam Pharmaceuticals had a negative return on equity of 41.08% and a negative net margin of 545.95%. Alnylam Pharmaceuticals’s revenue for the quarter was up 116.6% compared to the same quarter last year. During the same quarter last year, the company posted ($1.32) EPS. equities research analysts predict that Alnylam Pharmaceuticals will post -7.02 EPS for the current year.

A number of equities analysts recently issued reports on the stock. BidaskClub downgraded shares of Alnylam Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, April 4th. ValuEngine raised shares of Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, April 2nd. B. Riley reissued a “buy” rating and issued a $200.00 price target on shares of Alnylam Pharmaceuticals in a research note on Monday, April 2nd. Jefferies Group reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Monday, April 2nd. Finally, Evercore ISI assumed coverage on shares of Alnylam Pharmaceuticals in a research note on Wednesday, March 28th. They issued a “line” rating and a $143.00 price target for the company. Four research analysts have rated the stock with a sell rating, four have assigned a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company. Alnylam Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $134.15.

In other Alnylam Pharmaceuticals news, President Barry E. Greene sold 38,460 shares of the company’s stock in a transaction dated Wednesday, March 14th. The shares were sold at an average price of $143.10, for a total value of $5,503,626.00. Following the sale, the president now owns 97,544 shares in the company, valued at $13,958,546.40. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Laurie Keating sold 1,562 shares of the company’s stock in a transaction dated Tuesday, March 20th. The stock was sold at an average price of $149.83, for a total transaction of $234,034.46. Following the completion of the sale, the senior vice president now owns 16,062 shares in the company, valued at approximately $2,406,569.46. The disclosure for this sale can be found here. In the last 90 days, insiders sold 198,620 shares of company stock worth $28,404,143. Corporate insiders own 3.70% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This news story was reported by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this news story on another domain, it was copied illegally and republished in violation of international copyright and trademark legislation. The legal version of this news story can be read at https://stocknewstimes.com/2018/04/16/alnylam-pharmaceuticals-alny-getting-somewhat-positive-press-coverage-study-finds.html.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Insider Buying and Selling by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply